Tag: ASCO

The MIRASOL study (ClinicalTrials.gov identifier: NCT04209855), an international phase 3 randomized clinical trial, found that mirvetuximab soravtansine (Elahere™, ImmunoGen), an antibody-drug conjugate (ADC) and microtubule inhibitor, significantly improved progression-free and overall survival for women with platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha (FRɑ) expression.

Compared to Brentuximab Vedotin, Nivolumab Reduces Risk of Disease Progression in Untreated Hodgkin Lymphoma

During the annual meeting of the American Society of Clinical Oncology (ASCO) held June 2-6, 2023 in Chicago, Illinois, and online, cancer researchers and...

The use of trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival (PFS) compared to standard-of-care treatment with...

The treatment patients diagnosed with relapsed or relapsed/refractory multiple myeloma (RRMM), those who have relapsed or who are refractory to at least 1 line of...

Treatment with sacituzumab govitecan (Trodelvy®; Gilead Sciences), an antibody-drug conjugate (ADC), resulted in longer progression-free survival (PFS) compared to physician’s choice of chemotherapy in...

José Baselga, MD, Ph.D., an internationally renowned expert in the development of molecular targeted agents, the R&D chief at AstraZeneca, who had earlier been...

Initial data from the FORWARD II study (NCT02606305), a phase Ib/II study evaluating mirvetuximab soravtansine (also known as IMGN853), in combination with bevacizumab (Avastin®;...

Clinically meaningful topline results for a Phase II clinical trial of RC48-ADC were presented during the annual meeting of the American Society of Clinical...

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates or ADCs targeting cancers in areas of high...